You are here

Home » Content

Tumour Induced Osteomalacia: An Often-Missed Cause of Chronic Hypophosphatemia

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2017

Key Words:

Author Name
Abstract (2. Language): 
Significant hypophosphatemia in adult is uncommon, in which the most common culprit being Vitamin D deficiency. Hypophosphatemia in adults, require proper attention as it may indicate paraneoplastic effect of mesenchymal tumour (Fibroblast growth factor 23 secreting tumour). The diagnosis of such condition at early stage, along with prompt treatment can correct hypophosphatemia and improve the patient symptomatically. Here we are presenting a case of 48 years old female who had severe hypophosphatemia and on work up found to have FGF23 secreting mesenchymal tumour of the naso-ethmoid bone, surgical removal of which corrected hypophosphatemia and showed clinical improvement.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-tumour-induced-osteomalacia-often-missed-cause-chronic-hypophosphatemia.pdf
  • 11
54
57
  • English

REFERENCES

References: 

[1] Walton, R.J., and O.L.M. Bijvoet. “Nomogram for derivation of renal threshold phosphate concentration.” The
Lancet Vol. 306, No. 7929, 1975, p. 309-10.
[2] White, Kenneth E., et al. “The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide
overexpressed by tumors that cause phosphate wasting.” The Journal of Clinical Endocrinology & Metabolism
Vol. 86, No. 2, 2001, pp. 497-500.
[3] Jiang, Yan, et al. “Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia
in China: Report of 39 cases and review of the literature.” Journal of Bone and Mineral Research Vol. 27,
No. 9, 2012, pp. 1967-75.
[4] Weidner, Noel. “Review and update: oncogenic osteomalacia-rickets.” Ultrastructural Pathology Vol. 15, No.
4-5, 1991, pp. 317-33.
[5] Folpe, Andrew L., et al. “Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity:
an analysis of 32 cases and a comprehensive review of the literature.” The American Journal of Surgical Pathology
Vol. 28, No. 1, 2004, pp. 1-30.
[6] Khosravi, Azarmindokht, et al. “Determination of the elimination half-life of fibroblast growth factor-23.” The
Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 6, 2007, pp. 2374-77.
[7] Geller, Jordan L., et al. “Cinacalcet in the management of tumor-induced osteomalacia.” Journal of Bone and
Mineral Research Vol. 22, No. 6, 2007, pp. 931-37.
[8] Aono, Yukiko, et al. “Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.”
Journal of Bone and Mineral Research Vol. 24, No. 11, 2009, pp. 1879-88.

Thank you for copying data from http://www.arastirmax.com